J. Botbyl

发表

Tumor vascular proteins as biomarkers in ovarian cancer.

George Coukos, Dimitra Sasaroli, Raphael Sandaltzopoulos, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

A. Tan, J. Botbyl, J. Stephenson, 2013, Cancer Chemotherapy and Pharmacology.

A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer

J. Botbyl, A. Suttle, R. Ruiz-Soto, 2015, Investigational New Drugs.

Predictors of Regional Nodal Disease in Patients With Thin Melanomas

D. Elder, D. Guerry, P. Gimotty, 2006, Annals of Surgical Oncology.

In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort".

T. Rebbeck, P. Gimotty, A. DeMichele, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

Sung-Bae Kim, Y. Im, L. Cartee, 2013, Clinical pharmacology in drug development.

Effect of lapatinib on oral digoxin absorption in patients

Y. Bang, L. Cartee, J. Botbyl, 2015, Clinical pharmacology in drug development.

Mitotic Rate as a Predictor of Sentinel Lymph NodePositivity in Patients With Thin Melanomas

A. Alavi, D. Elder, D. Guerry, 2004, Annals of Surgical Oncology.

A population-based validation of the American Joint Committee on Cancer melanoma staging system.

D. Guerry, P. Gimotty, S. Soong, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.

D. Elder, D. Guerry, P. Gimotty, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment

L. Liotta, P. Gimotty, G. Coukos, 2006, Cancer biology & therapy.

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

E. Heath, J. Botbyl, W. Schelman, 2012, Cancer Chemotherapy and Pharmacology.

Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.

T. Rebbeck, B. Weber, P. Gimotty, 2005, Journal of Clinical Oncology.

Technetium Tc 99m sestamibi sensitivity in oxyphil cell-dominant parathyroid adenomas.

R. Weber, A. Chalian, P. Gimotty, 2006, Archives of otolaryngology--head & neck surgery.

Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib

P. LoRusso, J. Infante, D. Ouellet, 2015, Journal of clinical pharmacology.

Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation‐Positive Solid Tumors

D. Ouellet, R. A. Morrison, J. Botbyl, 2013, Journal of clinical pharmacology.

Predicting sentinel lymph node status in stage I/II melanoma

D. Elder, D. Guerry, P. Gimotty, 2005 .

A population-based validation of the AJCC melanoma staging system

D. Guerry, P. Gimotty, J. Botbyl, 2004 .

Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder

W. Bickel, K. Gatchalian, L. Marsch, 2020, Current medical research and opinion.

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

J. Schellens, A. Robidoux, L. Cartee, 2014, Investigational New Drugs.

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

R. Plummer, J. Botbyl, M. Scheulen, 2012, Cancer Chemotherapy and Pharmacology.

An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer

J. Botbyl, M. Mallath, P. Corrie, 2013, Investigational New Drugs.

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

M. Dawson, J. Botbyl, B. Huntly, 2018, Blood.

Safety and Efficacy of A Digital Therapeutic for Substance Use Disorder: Secondary Analysis of Data from A Nida Clinical Trials Network Study

E. Nunes, Hilary F Luderer, J. Botbyl, 2022, Substance abuse.

A Randomized Parallel-Group Study of Digital Gut-Directed Hypnotherapy vs Muscle Relaxation for Irritable Bowel Syndrome.

W. Chey, J. Botbyl, Sameer K Berry, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.